(reported by the Company)
No items found
Race Oncology is a specialty pharmaceutical company, whose business model is to pursue later stage drug assets, principally in the cancer field. Our first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies, before it was lost in a series of pharmaceutical mergers during the 1990s. Race Oncology is rediscovering Bisantrene. We own recent patent filings on Bisantrene and have secured Orphan Drug Designation in the US. Now our goal is to complete final development of Bisantrene and bring this valuable cancer drug to market.
|Category:||Health & biotech|
|ASX Listing Code (if applicable):||RAC|
|Year of Commencement:|
140 William Street, Level 40, Melbourne, Victoria 3000, AU